Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | DeFi: nirogacestat demonstrates improved PFS and ORR in progressing desmoid tumors

Tom Wei-Wu Chen, MD, National Taiwan University Hospital, Taipei, Taiwan, talk on The Phase III DeFi (NCT03785964) study of nirogacestat versus placebo for progressing desmoid tumors. The primary endpoint was progression-free survival (PFS) and secondary endpoints were safety, objective response rate (ORR), and patient-reported outcomes (PROs). The trial demonstrated statistically and clinically significant improvements in progression-free survival (PFS), objective response rates (ORR) and a manageable safety profile with nirogacestat versus placebo. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.